Skip to main content

Table 1 Tau antibodies tested in preclinical efficacy studies

From: A walk through tau therapeutic strategies

ANTIBODY EPITOPE ANIMAL MODEL IMPROVEMENT EFFICACY REFERENCE
Cognitive Motor NFTs Insoluble tau
PHF1 pS396/404 P301L nd. nd. nd. Reduced [56]
P301S nd. Improved Reduced Reduced
MC1 aa7–9 and aa 313–322 P301L nd. nd. nd. Reduced
P301S nd. Improved Reduced Reduced
MC1 aa7–9 and aa 313–322 P301L nd. nd. Reduced No change [72]
DA31 aa150–190 No change No change
PHF1 pSer396/404 Reduced Reduced
4E6G7 379-408 (pS396/404) P301L nd. nd. Reduced No change [129]
6B2G12
TOMA nd. Tg2576 Improved Improved nd. Reduced [54]
PHF6 pT231 rTg4510 Improved No change nd. No change [281]
PHF13 pS396 rTg4510 Improved No change nd. No change
PS19 Improved nd. Reduced No change
HJ9.3 aa306–320 P301S Improved No change Reduced Reduced [375]
HJ9.4 aa7–13 Moderate change No change Reduced No change
HJ8.5 aa25–30 Moderate change No change Reduced Reduced
HJ8.5 aa25–30 P301S nd. Improved Reduced Reduced [374]
43D aa6–18 3xTg-AD Improved nd. Reduced nd. [73]
77E9 aa184–195 Improved nd. Reduced nd.
AT8 pS202 + pT205 3xTg-AD nd. nd. Reduced nd. [342]
MAb86 pS422 TauPS2APP nd. nd. Reduced nd. [61]
pS404 mAb IgG2 pS404 K3 and pR5 nd. nd. Reduced Reduced [151]
pS409-tau pS409 P301L nd. nd. Reduced Reduced [182]
Armanezumab aa2–18 THY-Tau22 nd. nd. Reduced nd. [4]
PHF1 pS396/404 P301L nd. Improved Reduced No change [36]
Ta9 pS396 tau609 Improved nd. Reduced Reduced [328]
tau784
Ta4 pSer396 tau609 Improved No change Reduced Reduced
tau784
Ta1505 pSer413 tau609 Improved nd. Reduced Reduced
DC8E8 aa268-273, aa299-304, aa330-335, aa362-367 R3/m4 nd. nd. Reduced Reduced [168]
  1. nd Not defined